Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma

NCT04833504 · clinicaltrials.gov ↗

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B-cell Lymphoma
Mantle Cell Lymphoma
Transformed Follicular Lymphoma
Primary Mediastinal Large B-cell Lymphoma

Interventions

BIOLOGICAL: CD19 CAR-T Expressing IL7 and CCL19

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University